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Abstract 
 
Background and purpose 
The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate 
PB dose constraints based on dose-volume histograms (DVHs) in patients treated with prostate radiotherapy, and to identify clinical and 
dosimetric parameters that predict the risk of ED post prostate radiotherapy. 
 
Materials and methods 
Penile bulb DVHs were generated for 276 patients treated within the randomised IGRT substudy of the multicentre randomised trial, CHHiP. 
Incidence of ED in relation to dose and randomised IGRT groups were evaluated using Wilcoxon rank sum, Chi-squared test and atlases of 
complication incidence. Youden index was used to find dose-volume constraints that discriminated for ED. Multivariate analysis (MVA) of effect 
of dosimetry, clinical and patient-related variables was performed.  
 
Results  
Reduced treatment margins using IGRT (IGRT-R) produced significantly reduced mean PB dose compared with standard margins (IGRT-S) 
(median: 25Gy (IGRT-S) versus 11Gy (IGRT-R); p<0.0001). Significant difference in both mean (median: 23Gy (ED) vs. 18Gy (no ED); p=0.011) and 
maximum (median: 59Gy (ED) vs. 52Gy (no ED); p=0.018) PB doses between those with and without clinician reported ED were identified. Mean 
PB dose cut-point for ED was derived at around 20Gy. On MVA, PB mean dose and age predicted for impotence.  
 
Conclusion 
PB dose appears predictive of post-radiotherapy ED with calculated threshold mean dose of around 20Gy, substantially lower than published 
recommendations. IGRT-R enables favourable PB dosimetry and can be recommended provided prostate coverage is not compromised.  
 
ISRCTN: 97182923 
 
 
Introduction  
 
The current management options for localised prostate cancer enable excellent local tumour control with long term survival (1). However, 
prostate cancer and its treatment are the leading cause of cancer years lived with a disability (2). Evaluating treatment related toxicities is 
essential to inform patient decisions. There are limited data on the association of erectile dysfunction (ED) to external beam radiotherapy for 
prostate cancer, despite ED being the most commonly reported toxicity (3). ED can affect physical and psychosocial health and may profoundly 
effect the quality of life of patients and their partners (4–6).  
 
Pelvic radiation-induced complications have been shown to be dose and volume dependent and have been extensively explored for bowel and 
urinary toxicity (7). For ED post-radiotherapy there are uncertainties surrounding the most relevant normal tissues and the multifactorial causes 
of ED other than those attributable to the treatment. The penile bulb (PB) has attracted most interest as a critical normal tissue structure.   
 
Treatment planning dose objectives for the PB have been varied and inconsistent within the literature (8) and developed from data using older 
prostate radiotherapy techniques and dose fractionation schedules. More recently, prostate cancer has been found to have radiobiological 
features atypical of most other cancers and hypofractionation has been hypothesised as a method to improve the therapeutic ratio (9–11). In 
the largest randomised trial worldwide comparing conventional and hypofractionated radiotherapy (CHHiP), the long term side effects were 
similar with 2Gy and 3Gy fractionation schedules (9). Recommended PB dose constraints for hypofractionated schedules are not established (12) 
and those for standard fractionations from the QUANTEC papers need to be substantiated using data from patients treated with modern 
radiotherapy techniques (3).  
 
The primary aim of this study was to determine whether relationships exist between reduced target volume margins, PB dose and ED as assessed 
by clinician reported outcomes using both conventional and hypofractionated radiotherapy. The secondary aims were to derive radiotherapy 
dose constraints that could be implemented into radiotherapy planning to potentially decrease incidence of ED. Additionally, multivariate 
analysis (MVA) was performed to identify clinical and dosimetric parameters that predict risk of ED in patients treated with prostate image 
guided radiotherapy (IGRT).  
 
 
 
Materials and Methods 
 
 
The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy in Prostate Cancer; CRUK/06/016) study is a 
multicentre randomised controlled trial which used a three-arm design comparing conventionally fractionated radiotherapy (74Gy in 37 2Gy 
fractions (f)) with high-quality radiation techniques delivered using two different 3Gy hypofractionated radiotherapy dose schedules (60Gy in 
20f and 57Gy in 19f) (9).   
 
A multicentre randomised non-blinded IGRT substudy received approval by Central London REC1 Research Ethics Committee (10/H0718/31) on 
25th June 2010 and was implemented within the main CHHiP trial protocol (v 9.0). This substudy assessed acute and late toxicity associated with 
daily online IGRT and the feasibility of daily online IGRT delivery in a national trial. In the main CHHiP trial patients were randomised 1:1:1 to the 
fractionation schedules. Patients consenting to the IGRT substudy were also randomly allocated by minimisation, to (a) no daily online IGRT (i.e. 
centre standard verification methods) – using standard treatment planning margins, (b) daily online IGRT using standard treatment planning 
margins (IGRT-S), or (c) daily online IGRT with reduced treatment planning margins (IGRT-R). Centres had the option to randomise among all 3 
options or alternatively a versus b or b versus c to accommodate existing centre experience using IGRT (Figure E1, E2). The radiotherapy planning 
techniques have been previously described (13,14). Target volume dose coverage was achieved using a simultaneous integrated boost technique 
with mandatory and optimal normal tissue dose constraints (Table E1).  
 
The IGRT substudy commenced after the main CHHiP patient reported outcome (PRO) study had closed, an additional cross-sectional 
questionnaire study was approved by ethics (14/SW/1071) in September 2014.  
 
Data collection 
 
Patient demographic data was collected at trial entry. Clinician reported (CRO) ED, measured using Royal Marsden Hospital (RMH) erectile 
potency (EP) grading system, was prospectively recorded at baseline, pre-radiotherapy and at 6 monthly intervals up until 2 years post-
radiotherapy and thereafter annually. Grade 0 represented normal erection, grade 1 decreased erectile potency and grade 2 absent erectile 
function. Clinician reported Grade 2 EP was used as a toxicity endpoint, and patients were excluded from the analysis if baseline scores were 
reported as Grade 2. In the PRO substudy, data was collected at a single time point (at least 3 years from completing treatment) and included 
the use of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (EPIC-26 for sexual and hormonal domains)(15). A cut-point of 
33 for EPIC-26 sexual summary group score (16) was used as an endpoint. 
 
Dosimetry information, including full treatment planning data, was uploaded to a dedicated software platform, VODCA (MSS Inc, Hagendorn, 
Switzerland). 
  
 
Penile bulb dosimetric analysis 
 
PB was contoured retrospectively by one clinical oncologist (JM) (Figure E3) combining RTOG consensus panel atlas for pelvic normal tissue 
contouring guidelines (17), well-established  anatomic boundaries (18) and DUE-01 study guidelines (19). The lateral borders of the PB included 
the paired crura, anteriorly the corpus spongiosum and posteriorly the levator ani. The PB was outlined posterior to the urethra, with a round 
shape. The anterior border of the PB contour in the most cranial slice was used to guide the anterior border on the more caudal slices. Three-
dimensional physical dose distributions were converted into equivalent dose in 2Gy/f (EQD2) distributions by applying Withers formula (20) with 
/ = 3Gy (12,21) to each dose grid voxel. EQD2-based and physical dose-based PB dose-volume histogram data were exported from the analysis 
software. 
 
Dosimetric atlases of complication incidence (ACI) (22) were created using Matlab version R2016a (Mathworks, Natick, MA). ACI are a method 
of summarising toxicity and cumulative dose-volume data for an organ of interest, displayed as a dose-volume grid. Each box within the atlas 
describes a small range of dose and volume (5Gy and 10%, respectively) and presents a numeric fraction (i.e. denominator = patients whose DVH 
falls within the range of dose and volume of the box; numerator = number of patients whose DVH falls within the range of dose and volume of 
the box and who experienced grade 2 EP). PB mean, maximum dose and volume of PB receiving at least a defined dose were summarised. 
 
Statistical Methods 
 
PB dosimetry data were compared between patients with or without the toxicity endpoint using Wilcoxon rank sum with continuity correction. 
Exploratory analysis compared ED between the randomised groups using Chi-squared test of independence. Dose-volume constraints were 
derived using receiver operating characteristic (ROC) analysis for individual dose levels (EQD2 and physical dose) combined with toxicity data. 
The ‘Youden index’, J (23) was used to find the volume threshold for each dose level and the mean and maximum threshold doses that best 
discriminated between patients with or without toxicity. A dose metric was considered to be significantly better than chance at discriminating 
between patients with and without toxicity if the lower 95% confidence interval (CI) of the area under the ROC curve was greater than 0.5.  The 
incidence of toxicity in patients who met the derived constraints was compared with patients who failed the constraints.  
A correlation matrix was produced to check for high correlations between potential prognostic factors, in particular DVH parameters. Variables 
with Pearson correlation coefficients >0.80 were combined into a single variable (mean dose) to avoid the problem of multicollinearity, which 
may negatively affect generalisability of the model. PB mean and maximum dose and clinical variables listed in Table E6 were included in logistic 
regression models to predict RMH Grade 2 ED. To develop the prediction model, univariate logistic regression analysis assessed crude effect of 
each candidate variable on the defined endpoint of RMH Grade 2 EP at 2 years. 1000 bootstraps were used for each analysis. Multivariable 
prediction models used the variables significant from univariate analysis.  Normal tissue complication probability (NTCP) model was developed 
using multivariate logistic regression (R Development Core Team, R: A language and Environment for statistical computing, Version 3.3.1). Models 
were fitted using the packages glm (24) and leaps with 1000 bootstrap samples of equal size drawn at random with replacement. Models were 
fitted using logistic regression of the form Probability = eA(x) /1+eA(x) where A(x) = 0 +∑ 𝛽𝑥=𝑛𝑥=1 nxn, xn are the variables included in the model and 
n are the associated regression coefficients. The final models to predict RMH Grade 2 EP were assessed using the area under the ROC (AUC) 
and the goodness-of-fit of the chosen NTCP model was evaluated by the Hosmer-Lemeshow test (25). The chosen NTCP model for RMH Grade 
2 EP was externally validated using a random patient cohort from the main CHHiP trial where the PB had been outlined by a single clinician (AW) 
using the same PB contouring guidelines.  
 
 
Results  
 
Baseline characteristics of the 276 patients analysed are detailed in Table 1 and available data summarised in Figure 1. PB volume was similar 
(p=0.71) across randomised groups: median (IQR) was 6.3 (4.8-7.6) cm3 in the no IGRT group, 6.0 (4.9-7.8) cm3 in the IGRT-S group and 6.1 (4.8-
7.6) cm3 in the IGRT-R group. There were significant PB dose differences between patients treated with IGRT-S and IGRT-R for both mean and 
maximum PB dose (p<0.0001). Median values of mean (EQD2, alpha/beta 3Gy) PB doses were 35Gy, 25.3Gy and 10.8Gy and of maximum doses 
68.1Gy, 61.1Gy and 36.9Gy for no IGRT, IGRT-S and IGRT-R respectively (Figure 2).  
 
Erectile potency 
43/276 (16%) patients were excluded due to RMH Grade 2 EP at baseline. Of the remaining 233 patients, 191 patients reported year 2 RMH EP 
score. RMH Grade 2 EP at 2 years after radiotherapy was reported in 81/191 (42%) patients. 11/33 patients (33%) treated with no-IGRT had 
clinician reported ED compared to 37/78 (47%) in the IGRT-S and 33/80 (41%) in the IGRT-R groups respectively (not significantly different, 
p=0.37). The median (IQR) testosterone level at 12 months post randomisation in patients with Grade 2 EP was 9.9 (5.9-13.7)nmol/l compared 
with 12.2 (7.9-14.6)nmol/l in those reporting Grade 0/1 EP. Patient and clinical factors are grouped according to 2 year RMH EP score (Table E2). 
At 4 years, there were 70/163 (43%) patients with RMH Grade 2 EP, 31/66 (47%) were IGRT-S and 28/72 (39%) IGRT-R patients. Of those with 
Grade 2 EP at 2 years, 40/81 reported Grade 2 EP, 15/81 Grade 0 or 1 EP and the status unknown for 26 patients at 4 years. There were 146 
patients where the RMH EP status at year 2 and year 4 were recorded. Of these 45/146 (31%) patients had Grade 0 EP at 2 years, with 24/45 
(53%) patients retaining Grade 0 EP at 4 years, 17/45 (38%) reporting Grade 1 EP and 4/45 (9%) Grade 2 EP at this timepoint.   
 
Relationship of PB dose to erectile function 
Mean and maximum PB doses were significantly lower in patients with less severe ED post-radiotherapy. In patients with Grade 2 EP, their 
median (IQR) mean and maximum PB doses were 23Gy (8-40Gy) and 59Gy (32-69Gy) and in those patients with Grade 0/1 EP, it was 18Gy (8-
32Gy) and 52Gy (30-66Gy) respectively (Figure 3). ACI demonstrate the impact of PB dose and volume on erectile potency and shows a greater 
incidence of impotence at 2 years in patients whose DVH fell within the top right of the atlas compared to those within the bottom left, suggesting 
a PB dose-volume response (Figure 4). This association was also seen at year 3 and 4 endpoints (Figure E4). The dose volume histogram profiles 
distinguishing between those patients with and without RMH Grade 2 EP at 2 years show the association of Grade 2 EP with higher PB volumes 
receiving higher doses (Figure E5). Mean and maximum doses were 27.4(11.1-38.7)Gy and 61.8(42.6-69.0)Gy for patients with an EPIC-26 sexual 
summary group score <33 and 14.0(6.8-21.8)Gy and 43.0(20.5-63.5)Gy for patients with EPIC-26 sexual summary group score > 33 (p=0.001; 
Table E3). ACI (Figure E6/E7) further support a PB dose-volume response.   
 
Derivation of dose constraints  
Dose-volume constraints for ED using RMH scoring system over the range of 10-70Gy were derived (Table E4). The dose constraints (EQD2, 
alpha/beta 3Gy) derived for PB mean dose for CRO (RMH) severe ED was 20Gy (AUC(95%CI): 0.61(0.53-0.70)). The derived constraint for 
maximum PB dose was 56Gy (AUC(95%CI): 0.60(0.52-0.69)) for CRO (RMH). Patients who met these mean and maximum dose constraints were 
less likely to have RMH Grade 2 EP (OR: 0.38; 95%CI, 0.21-0.71 and 0.44; 95%CI, 0.24-0.82 respectively; Table E5). Similar derived PB mean dose 
constraints were seen with PRO (EPIC-26 sexual domain) severe ED of 22Gy (AUC(95% CI): 0.66(0.57-0.74)) and maximum PB dose of 55Gy 
(AUC(95% CI): 0.57(0.65-0.74)); Table E6.  
Dose-volume constraints were also derived using physical dose and RMH EP scoring system. Analysis from patients whose prescription dose was 
74Gy found a statistically significant derived mean dose constraint of 24Gy in 37 fractions (AUC(95% CI): 0.71(0.58-0.86), p=0.002). There was 
no statistically significant constraint using physical dose for patients prescribed 3Gy per fraction (Table E7).  
 
Development of NTCP model 
Univariate analysis demonstrated an association between age, diabetes, NCCN risk group and PB (EQD2, alpha/beta 3Gy) mean dose and 
impotence using the RMH EP grading scale (Table E8). Multivariate logistic regression analysis including these variables showed a relationship 
between PB mean dose and age (AUC(95%CI): 0.70(0.62-0.76)); (Figure 5). External validation of this model for ED using the RMH EP scale was 
performed using data from a random cohort of 232 patients treated within the main CHHiP trial (Table E9). 48 patients were not included as 
they had Grade 2 RMH EP at baseline, therefore 184 patients were evaluated in the NTCP model. The calculated AUC(95%CI) was 0.68(0.60-
0.76); Figure E8. 
 
Discussion 
 
ED is a critical health-related quality of life outcome in men treated for prostate cancer and the potential structures implicated in ED need to be 
determined. Previous data have suggested PB dose is associated with radiotherapy-induced ED (3,26). Modern radiotherapy techniques enable 
dose sculpting, causing steep dose gradients at the edge of the target volume (i.e. region of the PB) and IGRT improves treatment accuracy which 
permits reduced radiotherapy margins. The CHHiP IGRT trial provides a unique dataset to determine effect of PB dose on erectile function.  
 
We have demonstrated a relationship between reduced PTV margins enabled by IGRT and PB dose and relationship between PB dose and ED 
using CRO and PRO. Dose constraints for PB have been derived which are generalisable and could be implemented in radiotherapy planning. A 
consistent mean dose constraint of around 20Gy equivalent dose in 2Gy per fraction (Biologically Effective Dose = 33.6Gy using / = 3Gy) was 
derived and using the physical dose data for 2Gy fractionation, a statistically significant mean dose constraint of 24Gy was calculated, with a 
suggestion of a mean dose constraint of 22Gy for 3Gy fractionation  (Table E7). These constraints are similar to the PB mean dose threshold of 
20Gy determined in a smaller cohort (n = 41) treated with moderate hypofractionation (around 2.5Gy/f) (12). However, these thresholds are a 
significant reduction from the mean dose limit of 50Gy recommended in QUANTEC (3), and the 50Gy limit to 90% of PB suggested in the MRC 
RT01 trial (26). In our dataset, less than 7% of patients had PB mean doses of > 50Gy. The more favourable dose distributions in the present 
patient cohort may have enabled identification of lower discriminatory thresholds. Other potential reasons for these significant differences 
within the literature may include variation in penile bulb definition and contouring, different fractionation schedules and treatment techniques. 
In this study, we used a single outlining clinician for hypotheses generating and validation cohorts to remove inter-observer variability inherent 
in PB contouring, which has been shown to impact on DVH parameters (19). Fractionation schedules were protocol defined and IMRT +/- IGRT 
was used in all cases. Our results are in accord with an interim analysis of the DUE-01 study which found maximum PB dose as a predictive factor 
for ED (21). However, due to the small PB volume and potential substantial impact inter-observer contouring variability has on dose-volume 
parameters (19), we suggest that mean PB dose is likely to be a more robust metric for use in radiotherapy planning. 
 
ED post-radiotherapy is multifactorial and although PB dose is associated with ED, it may be a surrogate for surrounding structures, such as 
neurovascular bundles and internal pudendal arteries, which are not easily visualised on CT, but can be seen on MRI (27). Further studies using 
MR planning will enable interrogation of these structures to determine associated dose volume relationships with ED. Although the PB is best 
identified on MRI, it is visible on CT and, hence, a recognised structure of interest within the RTOG contouring atlas (17). The introduction of 
MRI-based treatment planning and image guidance permits more accurate identification of the prostate apex and PB during treatment planning 
and delivery, which may enable PB sparing. Additionally, although planning target volume coverage should not be jeopardised, the creation of 
PB as an objective function for prostate radiotherapy optimisation should be considered. This goal appears feasible as around 50% of patients 
within the whole cohort achieved a PB mean dose < 20 Gy, approaching 80% for patients within the IGRT-R group. 
 
Radiotherapy dose constraints provide a practical means of using dose-response relationships to inform radiotherapy planning in an evidence-
based manner. A dose threshold constraint is the best cut point in the data, being used as a proxy for the whole dose-volume complication 
distribution. Further benefit may be seen reducing the mean PB dose as far as possible, without compromising other aspects of the treatment 
plan.  
 
Limitations of this study include that the sub-study was not powered to compare the randomised groups and the single time-point assessment 
of PRO. However, this is the largest reported multicentre series of patients evaluating ED post-radiotherapy using both CRO and PRO. Results 
have shown significant and consistent association between PB dose and ED independent of scoring system, strengthening validity of these 
findings.   
 
To our knowledge this predictive model for EBRT induced erectile dysfunction is the first to include PB dose. The derived model also included 
age, which is an established risk factor for ED after treatment (28,29). The discriminative power of the final multivariable model was good, with 
AUC=0.70. External validation of the model showed moderate discriminative power (AUC=0.68), giving a very favourable optimism factor with 
this model (0.02). However, the similar radiotherapy treatment characteristics and inclusion / exclusion criteria for both cohorts may partly 
explain this concordance in model performance described. Further analyses with additional datasets should be pursued. 
 
ED is multifactorial and this study has explored limited clinical factors, with patients who reported baseline impairment being excluded from 
analysis. In addition, the median 12 month testosterone levels in those patients with reported RMH Grade 2 EP was above the postulated 
threshold of 8nmol/l, where the relationship between testosterone and sexual functioning is very low (30). Larger studies interrogating role of 
PB dose in post-radiotherapy ED should be encouraged, with further refinement and validation of clinical prediction models. The aim will be to 
enable personalised discussion of the risks for radiation-related ED and support clinical decision-making. 
 
 
 
Acknowledgements: 
 
We thank the patients and all investigators and research support staff at the participating centres, Trial Management Group members past and present and the Independent 
Data Monitoring Committee (Matthew Sydes [chair], Christopher Tyrell, Peter Barrett-Lee and, previously, Peter Hoskin, Christopher Nutting) and Trial Steering Committee 
(Anthony Zietman [chair], Soren Bentzen, Vivian Cosgrove, Heather Payne) for overseeing the trial. We acknowledge support of Cancer Research UK (C8262/A7253, 
C1491/A9895, C1491/A15955, SP2312/021), the National Institute for Health Research (NIHR) Cancer Research Network, and DD,JM,SG, CG, EH acknowledge NHS funding 
to the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London which specifically funded the PRO study 
(A84).  
 
References: 
1.  Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for 
Localized Prostate Cancer. N Engl J Med [Internet]. 2016;375(15):1415–24. Available from: 
http://www.nejm.org/doi/10.1056/NEJMoa1606220 
2.  Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: A systematic analysis 
of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840–50.  
3.  Roach  3rd M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol 
Phys [Internet]. 2010/03/05. 2010;76(3 Suppl):S130-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20171507 
4.  Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinklay JB. Impotence and its medical and physiological correlates: results of the 
Massacheusetts male aging study. J Urol. 1994;151:54–61.  
5.  Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples I: Couple conceptions of ED. J Sex 
Med. 2009;6(10):2746–60.  
6.  Salonia A, Castagna G, Saccà A, Ferrari M, Capitanio U, Castiglione F, et al. Is Erectile Dysfunction a Reliable Proxy of General Male Health 
Status? The Case for the International Index of Erectile Function-Erectile Function Domain. J Sex Med. 2012;9(10):2708–15.  
7.  Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 
[Internet]. 2009/09/22. 2009;93(2):153–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19765845 
8.  Rivin del Campo E, Thomas K, Weinberg V, Roach M. Erectile dysfunction after radiotherapy for prostate cancer: a model assessing the 
conflicting literature on dose-volume effects. Int J Impot Res [Internet]. 2013;25(5):161–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23784555 
9.  Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-
modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 
[Internet]. 2016;17(8):1047–60. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S1470204516301024%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/27339115%5Cnhttp://ww
w.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4961874 
10.  Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two 
radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.  
11.  Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy 
for prostate cancer. J Clin Oncol [Internet]. 2013;31(31):3860–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24101042 
12.  McDonald AM, Baker CB, Shekar K, Popple RA, Clark GM, Yang ES, et al. Reduced radiation tolerance of penile structures associated with 
dose-escalated hypofractionated prostate radiotherapy. Urology. 2014;84(6):1383–8.  
13.  South CP, Khoo VS, Naismith O, Norman A, Dearnaley DP. A comparison of treatment planning techniques used in two randomised UK 
external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) [Internet]. 2008;20(1):15–21. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18054471 
14.  Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the 
CHHiP trial. Clin Oncol (R Coll Radiol) [Internet]. 2007/11/27. 2008;20(1):12–4. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18036791 
15.  Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index 
composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology [Internet]. 2010;76(5):1245–
50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20350762 
16.  Wheat JC, Hedgepeth RC, He C, Zhang L, Wood DP. Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form 
Sexual Summary Score. J Urol. 2009;182(6):2844–9.  
17.  Gay HA, Barthold HJ, O’Meara E, Bosch WR, El Naqa I, Al-Lozi R, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a 
radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys [Internet]. 2012/04/10. 2012;83(3):e353-62. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/22483697 
18.  Wallner KE, Merrick GS, Benson ML, Butler WM, Maki J, Tollenaar BG. Penile bulb imaging. Int J Radiat Oncol Biol Phys [Internet]. 
2002/07/04. 2002;53(4):928–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12095559 
19.  Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, Valdagni R, et al. Inter-observer variability in contouring the penile bulb on CT images 
for prostate cancer treatment planning. Radiat Oncol [Internet]. 2011;6:123. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21943002 
20.  Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1(2):187–91.  
21.  Cozzarini C, Rancati T, Badenchini F, Palorini F, Avuzzi B, Claudio ·, et al. Baseline status and dose to the penile bulb predict impotence 1 
year after radiotherapy for prostate cancer. Strahlentherapie und Onkol. 2016;192:297–304.  
22.  Jackson A, Yorke ED, Rosenzweig KE. The Atlas of Complication Incidence: A Proposal for a New Standard for Reporting the Results of 
Radiotherapy Protocols. Semin Radiat Oncol. 2006;16(4):260–8.  
23.  Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.  
24.  Morgan JA, Tatar JF. Calculation of the residual sum of squares for all possible regressions. Technometrics [Internet]. 1972;14(2):317–25. 
Available from: http://links.jstor.org/sici?sici=0040-1706(197205)14:2%3C317:COTRSO%3E2.0.CO;2-7 
25.  Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 
1997;16(9):965–80.  
26.  Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S, et al. Evaluating the relationship between erectile dysfunction and dose 
received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, 
ISRCTN47772397). Radiother Oncol [Internet]. 2006/09/05. 2006;80(3):355–62. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16949694 
27.  Rabbani F, Stapleton  a M, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J 
Urol. 2000;164(6):1929–34.  
28.  Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with 
adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology [Internet]. 2002;59(4):480–4. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11927294 
29.  Huyghe E, Delaunay B, Njomnang Soh P, Delannes M, Walschaerts M, Delavierre D, et al. Proposal for a predictive model of erectile 
function after permanent 125 i prostate brachytherapy for localized prostate cancer. Int J Impot Res [Internet]. 2013;25:121–6. Available 
from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52465468 
30.  O’Connor DB, Lee DM, Corona G, Forti G, Tajar A, O’Neill TW, et al. The relationships between sex hormones and sexual function in middle-
aged and older European men. J Clin Endocrinol Metab. 2011;96(10).  
 
 
Figure Captions 
 Figure 1: Trial profile (*endpoints assessable means those patients with DICOM data and complete endpoint data for evaluation) 
DICOM: Digital imaging and Communications in medicine and is a standard for storing and transmitting medical images; F: fractions 
 
Figure 2: Boxplots illustrating the dose distribution for the calculated dose (Gy) of the penile bulb by IGRT group. IGRT: image guided 
radiotherapy; IGRT-R: IGRT with reduced margins; IGRT-S: IGRT with standard margins 
 
Figure 3: Boxplots summarising the impact of penile bulb dosimetry on the defined toxicity endpoints using clinician (RMH) reported outcomes. 
Defined endpoints: RMH Grade 2 EP; 0=no; 1=yes. p values determined by Wilcoxon rank sum.  
 
Figure 4: Atlases of complication incidence for RMH Grade 2 erectile potency at 2 years in (A) all patients with recorded erectile potency at 2 
years and (B) patients treated with IGRT (standard and reduced margins) with recorded erectile potency at 2 years. Dose (Gy) is the equivalent 
dose in 2Gy/F using alpha/beta ratio of 3Gy. The colour of the box is determined by the fractional incidence of the endpoint, with the orange to 
red representing 70-100%. 
 
Figure 5: (A) Chosen model variables, regression coefficient, multiplication values for the variables included in the model and metrics exploring 
the performance of the model. (B) ROC curve obtained applying model for RMH Grade 2 EP and calibration plot for internal validation. The circles 
represent the Hosmer-Lemeshow groups, the solid line represents the identity line.  
 
 
 
 
 
 
 
Figure 1: Trial profile (*endpoints assessable means patients with DICOM data and complete endpoint data) 
 
 
 
 
 
 
Figure 2: Boxplots illustrating dose distribution for PB calculated dose (Gy) by IGRT group. 
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Figure 3: Boxplots summarising impact of PB dosimetry on CRO toxicity endpoints. Defined endpoints: Grade 2 EP; 0=no; 1=yes. p values 
determined by Wilcoxon rank sum.  
 
 
A B
Figure 4: ACI for Grade 2 EP at 2 years in (A) all patients with recorded EP at 2 years and (B) patients treated with IGRT with recorded EP at 2 
years; (Dose = EQD2,alpha/beta 3Gy) 
 
 
 
 
 
 
 
 Model Variables Regression 
coefficient
95% CI Multiplication value AUC CI
Hosmer-
Lemeshow 
test
RMH EP Constant
Age
PB mean dose
-8.79
0.12
0.02
-12.93 to -4.23
0.053 to 0.17
-0.0007 to 0.035
-
Age in years
Dose in Gy
0.70 0.62-0.76 Chi square: 6.64
p=0.5757
(model does fit 
the data well)
Figure 5: (A) Chosen model variables, regression coefficient, multiplication values for variables included in model and metrics exploring 
performance of model. (B) ROC curve obtained applying model for Grade 2 EP and calibration plot for internal validation. Circles represent 
Hosmer-Lemeshow groups, solid line represents identity line.  
 
 
  
No IGRT 
N=46 
n (%) 
IGRT - S 
N=129 
n (%) 
IGRT - R 
N=101 
n (%) 
Main CHHiP 
trial  
N=3216 
n (%) 
Age at registration (years)     
Median (IQR) 70 (66-73) 72 (66-75) 71 (67-75) 69 (44-85) 
     
T stage (clinical assessment)     
T1 14 (30) 41 (32) 40 (40) 1170 (36) 
T2 27 (59) 80 (62) 54 (53) 1766 (55) 
T3 5 (11) 8 (6) 7 (7) 277 (9) 
PSA (pre-hormone treatment) 
(ng/ml)    
 
Median (IQR) 9.5 (6.6-13.8) 9.6 (6.5-12.5) 8 (6.8-11.3) 10 (7-15) 
NCCN Risk group     
Low 2 (4) 13 (10) 17 (17) 484 (15) 
Medium 36 (78) 104 (81) 75 (74) 2347 (73) 
High 8  (17) 12 (9) 9 (9) 385 (12) 
CHHiP treatment allocation 
74Gy/37Fr 
60Gy/20Fr 
57Gy/19Fr 
16 (35) 
15 (32.5) 
15 (32.5) 
41 (32) 
45 (35) 
43 (33) 
30 (29) 
35 (35) 
36 (36) 
 
1065 (33) 
1074 (33) 
1077 (34) 
Hormone therapy 
None 
Bicalutamide monotherapy 
LHRH agonist 
Unknown 
1 (2) 
6 (13) 
39 (85) 
0 (0) 
3 (2) 
29 (23) 
96 (74) 
1 (1) 
4 (4) 
21 (21) 
74 (73) 
2 (2) 
 
90 (3) 
403 (13) 
2700 (83) 
9 (<1) 
Duration of hormone therapy  
Median (IQR) in days 107 (94-161) 145 (112-178) 147 (121-161) 
 
168 (133-196) 
Diabetes 6 (13) 14 (11) 10 (10)  
Yes 
No 
Unknown 
40 (87) 
 
107 (83) 
8 (6) 
83 (82) 
8 (8) 
342 (11) 
NA 
NA 
Hypertension 
Yes 
No 
Unknown 
20 (43) 
25 (54) 
1 (2) 
 
53 (41) 
68 (53) 
8 (6) 
33 (33) 
60 (59) 
8 (8) 
 
1276 (40) 
NA 
NA 
 
Table 1: Baseline demographics, clinical characteristics, and treatment details by randomised group. 
NCCN: National Comprehensive Cancer Network 
 
 
Highlights: 
 
 Dosimetric benefits to the penile bulb was seen in patients treated with IGRT and reduced CTV-PTV margins 
 Patients who had a lower planned dose to the penile bulb reported less erectile dysfunction 
 A threshold mean penile bulb dose for erectile dysfunction was determined to around 20Gy. 
 
 
